Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
2
×
boston blog main
boston top stories
boston university
2
×
clinical trials
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
2
×
abbvie
adalimumab (humira)
aducanumab
aduro biotech
affordable care act
akcea therapeutics
alez azar
alnylam pharmaceuticals
alzheimer's disease
antibiotics
axial spondyloarthritis
barry greene
bausch health
biogen
boston
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
cancer
cancer immunotherapy
car-t immunotherapy
cell therapy
cluster headache
crispr
dan ollendorf
deals
What
ago
alnylam
approval
approve
awaits
bio
biogen’s
biological
biopharmaceutical
companies
convo
crossed
decades
decision
discovered
drug
earlier
failures
fda
fingers
friday
historic
littered
medicine
nash
new
news
patients
price
remains
rna
road
roundup
strategy
talk
time
trick
uses
Language
Current search:
biotech
×
" boston university "
×
" san francisco top stories "
×
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision